Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Trials
Study of Oral MRT-2359 in Selected Cancer Patients

trialsTrialActive

Study of Oral MRT-2359 in Selected Cancer Patients

A phase 1/2 trial of Oral MRT-2359 in non-small-cell lung cancer, small-cell lung cancer, neuroendocrine tumours, HR-positive / HER2-negative breast cancer and prostate cancer, run by Monte Rosa Therapeutics, Inc, active and no longer recruiting.

Overview Connected6

Overview

Study of Oral MRT-2359 in Selected Cancer Patients is a phase 1/2 interventional study registered as NCT05546268 by Monte Rosa Therapeutics, Inc, with 174 participants enrolled, started 2022-10-12 and due to reach its primary completion in 2026-05. Interventions recorded: Oral MRT-2359.

Setting

A Phase 1/2 Study of Oral MRT-2359 in Patients With MYC-Driven and Other Selected Solid Tumors Including Lung Cancer and Diffuse B-Cell Lymphoma

Phase

Phase 1/2

Sponsor

Monte Rosa Therapeutics, Inc

Registry

Started

2022-10-12

Enrolled

174 enrolled

Connected

Similar pages

Treatment
PF-07248144
Shares HR-positive / HER2-negative breast cancer, Prostate cancer, Non-small-cell lung cancer and the tag pipeline.
Trial
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Trial
Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Trial
A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Trial
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Trial
TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
Shares Prostate cancer, Non-small-cell lung cancer and the tag pipeline.
Trial
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
Shares Neuroendocrine tumours, Small-cell lung cancer and the tag pipeline.
Trial
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
Shares Neuroendocrine tumours, Small-cell lung cancer and the tag pipeline.

cancers

HR-positive / HER2-negative breast cancer Neuroendocrine tumours Non-small-cell lung cancer Prostate cancer Small-cell lung cancer

companies

Monte Rosa Therapeutics

Evidence strength19/100 · Preliminary

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 1/2+8
174 enrolled+11
No structured primary endpoint0
Result: active0
No independent replication recorded0

Formula disclosed on the evidence page.

ProvenanceLast edited 2026-09-16 · Jude Gomila · Registry trials wave 6 and products wave 7 · diff · file

Sources & links

ClinicalTrials.gov NCT05546268

Data

JSON ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
Report a readout
How review works

Cancers

Non-small-cell lung cancer
Small-cell lung cancer
Neuroendocrine tumours
HR-positive / HER2-negative breast cancer
Prostate cancer

Companies

Monte Rosa Therapeutics

Not yet reviewedNeeds expert (clinical) review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Machine-readable versions of Study of Oral MRT-2359 in Selected Cancer Patients

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/trials/nct05546268/)
All trials as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id nct05546268.

WebMCP tools registered on this page: onco_search, onco_get_entity.